Drug Patents owned by Glenmark Specialty

1. Drug name - RYALTRIS

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10765686 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10758550 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10646500 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10548907 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10016443 GLENMARK SPECIALTY Treatment of allergic rhinitis using a combination of mometasone and olopatadine Sep, 2034

(11 years from now)

US10517880 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9750754 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9078923 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9937189 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10376526 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US9370483 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

US10561672 GLENMARK SPECIALTY Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine Sep, 2034

(11 years from now)

Drugs and Companies using MOMETASONE FUROATE; OLOPATADINE HYDROCHLORIDE ingredient

Treatment: Method of delivering a combination of olopatadine hydrochloride and mometasone furoate to a nasal airway; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate to a pediatric patient; Treatment of seasonal allergic rhinitis by nasaly administering a combination of olopatadine hydrochloride and mometasone furoate

Dosage: SPRAY, METERED;NASAL

More Information on Dosage
Strength Dosage Availability
0.025MG/SPRAY;0.665MG/SPRAY SPRAY, METERED;NASAL Prescription

availability in other generic markets.

Click on the highlighted region to filter.